United Therapeutics (NASDAQ:UTHR – Get Free Report) released its earnings results on Wednesday. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23, Briefing.com reports. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter last year, the company earned $5.38 EPS. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis.
United Therapeutics Trading Up 1.7 %
Shares of UTHR stock traded up $6.10 during trading hours on Thursday, reaching $367.50. 243,835 shares of the stock traded hands, compared to its average volume of 465,227. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $16.30 billion, a PE ratio of 17.12, a PEG ratio of 1.27 and a beta of 0.57. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $377.03. The business has a fifty day moving average price of $354.34 and a 200 day moving average price of $315.28.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Jefferies Financial Group increased their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. UBS Group raised their target price on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $366.23.
Insider Buying and Selling
In other news, Director Raymond Dwek sold 5,000 shares of the stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at $569,362.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Raymond Dwek sold 5,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the sale, the chief financial officer now owns 6,426 shares of the company’s stock, valued at approximately $2,358,277.74. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 107,012 shares of company stock valued at $36,767,286. Company insiders own 12.50% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Five stocks we like better than United Therapeutics
- How to Calculate Stock Profit
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Using the MarketBeat Stock Split Calculator
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What Makes a Stock a Good Dividend Stock?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.